New drug duo aims to stop bladder cancer from coming back
NCT ID NCT07646145
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a combination of two drugs—disitamab vedotin given through a vein and mitomycin C placed directly into the bladder—in 30 people with a specific type of non-muscle-invasive bladder cancer that has a protein called HER2. The goal is to see if this treatment can reduce the risk of the cancer returning and help patients avoid more aggressive surgery to remove the bladder.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Disitamab vedotin (an antibody-drug conjugate) and mitomycin C (a chemotherapy drug given directly into the bladder)
- What this could lead to
- If this works, it could offer a new treatment option that lowers the chance of bladder cancer coming back and helps patients avoid needing their bladder removed.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination of drugs may cause side effects, and it is not yet known if it works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, Shanxi, 030000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy beat bladder cancer without surgery?
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Herbal formula aims to stop bladder Cancer's return
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- Combining two drugs may tackle bladder cancer that resists standard therapy
- Microscopic clues may forecast bladder Cancer's next move